Bristol Myers Squibb increased its dividend by 1.6%, marking 17 consecutive years of raises, with a current yield of about 4.2%. Despite strong growth in newer drugs like Camzyos and Eliquis, the company faces challenges from patent expirations, notably Eliquis in 2028, and carries $43 billion in debt. The dividend payout remains sustainable at about 36%-37% of earnings, supported by strong cash flow, but future increases may be limited as the company prioritizes debt reduction and navigates patent risks. Investors should watch upcoming data on milvexian, a potential Eliquis replacement, to gauge dividend growth prospects post-2028.
Bristol Myers Squibb's dividend yield of 4.16% on Pluang compares favorably to its 52-week price range of USD 42.60 to USD 68.09, with the current price at USD 60.55 as of Oct 17, 2026 01:02 WIB. Despite a slight 1-day price dip of 0.03%, investor interest remains strong with 100% buy orders on the platform. This suggests that the stock's income appeal is balanced against its recent price performance and ongoing patent challenges.
BlackLine announced the winners of its 2026 Modern Accounting Awards, recognizing six leading companies—Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US Foods—for pioneering modern finance operations. These firms ha...
Bristol-Myers Squibb's shares fell 3% after its experimental cancer drug RYZ101 showed significant improvement in progression-free survival in a Phase 3 trial for advanced gastroenteropancreatic neuroendocrine tumors. The drug, developed by Bristol-M...
